Allogene Therapeutics
Stock Forecast, Prediction & Price Target
Allogene Therapeutics Financial Estimates
Allogene Therapeutics Revenue Estimates
Allogene Therapeutics EBITDA Estimates
Allogene Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $38.48M N/A | $243K -99.36% | $95K -60.90% | Avg: $3.92M Low: $2.80M High: $5.60M avg. 4030.06% | Avg: $24.23M Low: $2.26M High: $172.10M avg. 517.57% | Avg: $127.17M Low: $11.88M High: $903.27M avg. 424.83% | Avg: $223.30M Low: $20.86M High: $1.58B avg. 75.59% |
Net Income
% change YoY
| $-244.83M N/A | $-329.81M -34.70% | $-327.26M 0.77% | Avg: $-300.98M Low: $-338.97M High: $-189.15M avg. 8.03% | Avg: $-327.63M Low: $-354.66M High: $-147.51M avg. -8.85% | Avg: $-197.84M Low: $-1.76B High: $35.31M avg. 39.61% | Avg: $-116.75M Low: $-1.04B High: $20.84M avg. 40.98% |
EBITDA
% change YoY
| $-255.79M N/A | $-335.44M -31.14% | $-300.29M 10.48% | Avg: $-784.71K Low: $-1.12M High: $-560.50K avg. 99.73% | Avg: $-4.84M Low: $-34.42M High: $-452.91K avg. -517.57% | Avg: $-25.43M Low: $-180.65M High: $-2.37M avg. -424.83% | Avg: $-44.66M Low: $-317.21M High: $-4.17M avg. -75.59% |
EPS
% change YoY
| -$1.8 N/A | -$2.3 -27.77% | -$2.09 9.13% | Avg: -$1.56 Low: -$2.16 High: -$1.21 avg. 25.24% | Avg: -$1.64 Low: -$2.26 High: -$0.94 avg. -4.68% | Avg: -$1.26 Low: -$11.26 High: $0.23 avg. 22.91% | Avg: -$0.74 Low: -$6.65 High: $0.13 avg. 40.98% |
Operating Expenses
% change YoY
| $294.28M N/A | $335.69M 14.07% | $327.83M -2.34% | Avg: $851.20M Low: $608.00M High: $1.21B avg. 159.64% | Avg: $5.25B Low: $491.28M High: $37.33B avg. 517.57% | Avg: $27.58B Low: $2.57B High: $195.96B avg. 424.83% | Avg: $48.44B Low: $4.52B High: $344.09B avg. 75.59% |
FAQ
What is Allogene Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 19.94% in 2025-2028.
We have gathered data from 15 analysts. Their low estimate is -338.97M, average is -300.98M and high is -189.15M.
What is Allogene Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 1262.01% in 2025-2028.
We have gathered data from 12 analysts. Their low revenue estimate is $2.80M, average is $3.92M and high is $5.60M.
What is Allogene Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 21.11% in 2025-2028.
We have gathered data from 15 analysts. Their low earnings per share estimate is -$2.16, average is -$1.56 and high is $-1.20.
What is the best performing analyst?
In the last twelve months analysts have been covering Allogene Therapeutics stock. The most successful analyst is Kalpit Patel.